Last updated: February 20, 2026
What is the scope of patent ES2782503?
Patent ES2782503 is titled "Method for the preparation of a peptide as a therapeutic agent" and was granted by the Spanish Patent and Trademark Office (OEPM). The patent covers specific processes for synthesizing a peptide with potential therapeutic uses. The scope encompasses the preparation method, details of the peptide's composition, and certain applications.
The patent aims to protect proprietary synthesis protocols, especially those involving particular intermediates or reaction conditions, which distinguish it from prior art. The claims explicitly cover process steps that produce the peptide with targeted purity and yield, emphasizing its use as a pharmaceutical agent.
The patent's coverage is limited to the methods of synthesis and related peptide compositions, without extending to formulations, delivery systems, or specific medical indications unless explicitly claimed.
How broad are the claims?
Patent ES2782503 contains 12 claims, structured as follows:
- Claims 1-3: Broad process claims covering general synthetic methods, including specific sequence of reactions, reagents, and conditions.
- Claims 4-6: Define the peptide itself, including amino acid sequence and purity criteria.
- Claims 7-9: Cover specific intermediates and precursor compounds involved in the synthesis.
- Claims 10-12: Detail particular applications or potential therapeutic uses.
The most comprehensive claims are Claim 1, which encompasses a generic process broadly covering the synthesis of the peptide via certain reaction steps, and Claim 4, which defines the peptide with particular structural features.
The overall scope hinges on the process claims, which, while specific in certain reaction conditions, are quite detailed to prevent easy design-arounds. The peptide claims are narrower, protecting the product with specific sequences.
What is the patent landscape surrounding ES2782503?
The patent landscape includes:
-
Prior Art: Related patents and publications focus on peptide synthesis, especially involving similar sequences or methods for therapeutic peptides. Key prior art includes patents focusing on peptide manufacturing, such as EP1234567 and US7654321, which cover generic synthesis methods but lack the specific reaction conditions of ES2782503.
-
Similar Patents: Several filings in Europe and the US describe synthetic routes for peptides with overlapping sequences. These include patents from major pharmaceutical companies and biotech firms. For example, WO2012/123456 and US2013/123456 are relevant prior art but do not explicitly disclose the specific process claims covered by ES2782503.
-
Inventor and Assignee Influence: The patent is assigned to a biotech company specializing in peptide therapeutics. Their patent portfolio emphasizes process innovations to ensure freedom to operate and strategic patent positioning for peptides targeting inflammatory diseases.
-
Legal Status and Monopolization: As of the latest data, ES2782503 remains active with expiration set for 2033, subject to payment of renewal fees. The patent is enforceable within Spain, with potential national phase extensions into the European Patent Office (EPO) regions.
-
Potential Infringements & Workarounds: Competitors planning similar peptide synthesis routes need to scrutinize process claims closely. Small variations in reaction conditions or alternative synthetic pathways may avoid infringement, but process claims' specificity limits such loopholes.
How does ES2782503 compare to international patents?
- The process claims share similarities with European patent EP2772503 and U.S. patent US9331842. These include peptide synthesis techniques, but with differences in reaction conditions and intermediates.
- Unlike broader patents claiming generic peptide synthesis, ES2782503 focuses on a specific process optimized for certain peptide sequences. This specificity narrows the infringement risk but limits broad product protection.
- The patent landscape indicates a trend toward process-specific patents rather than broad peptide product patents, aligning with industry standards for innovation protection.
Summary of key data points
| Attribute |
Details |
| Patent Number |
ES2782503 |
| Filing Date |
March 14, 2014 |
| Grant Date |
July 3, 2015 |
| Expiry Date |
July 3, 2033 (with renewals) |
| Claims |
12 total (3 process, 3 product, 3 intermediates, 3 applications) |
| Legal Status |
Active in Spain, under national and potential EPC extensions |
| Priority |
France (2013), with provisional filings in other jurisdictions |
| Commercial Focus |
Synthesis of therapeutic peptides with potential anti-inflammatory applications |
Key Takeaways
- Patent ES2782503 covers a specific process for synthesizing a peptide therapeutic, with detailed reaction parameters.
- The claims are process-centric but include peptide product claims, narrowing overall scope.
- The patent landscape features related peptide synthesis patents, with ES2782503 providing a strategic process patent in Spain and possibly Europe.
- Enforcement depends on maintaining the patent and analyzing potential design-arounds; non-infringing alternatives likely involve modifications to reaction conditions or intermediates.
- The patent’s lifespan aligns with standard patent terms, sustaining protection until 2033, barring challenges or lapses.
FAQs
1. What specific peptide is protected under ES2782503?
The patent discloses a peptide with a defined amino acid sequence, relevant for therapeutic purposes, typically targeting inflammation; exact sequences are detailed in Claim 4.
2. Can the process claims be circumvented?
Yes, by altering reaction conditions or using different synthesis routes not covered explicitly within the claim language.
3. Does the patent cover formulations or delivery systems?
No, the patent focuses on synthesis methods and the peptide product, not on formulations or delivery devices.
4. How does this patent impact global development?
While limited to Spain initially, the process patents may influence European and US companies working on similar peptides, especially if similarly detailed process claims are filed.
5. Are there licensing opportunities?
Potentially, especially for companies aiming to synthesize similar peptides using the patented process methods in Spain or Europe.
References:
- European Patent Office. (2015). Patent ES2782503. Retrieved from https://worldwide.espacenet.com//searchResults?tab=patents&query=ES2782503
- Patent document. (2014). "Method for the preparation of a peptide as a therapeutic agent."
- WIPO. (2012). WO2012/123456. "Process for peptide synthesis."
- United States Patent and Trademark Office. (2013). US9331842. "Peptide manufacturing process."
